Global science-led UK healthcare company GlaxoSmithKline (GSK) has announced a new manufacturing agreement with our healthcare subsidiary, Bioventure Healthcare FZE (previously known as Geltec Healthcare FZE). Through this venture, GSK will transfer to the UAE the secondary packaging of 20 of its key products across several therapy areas, including the central nervous system, dermatology, urology,

GlobalOne Healthcare Holding (GHH), our Healthcare Division, announced the rebranding of its subsidiary Geltec Healthcare FZE as Bioventure Healthcare FZE, as part of its strategy to strengthen its business and drive growth in the pharmaceutical and supplement manufacturing industry.   A strategic partner of multi-national companies and a key exporter to the U.S., Bioventure Healthcare

Bioventure, a subsidiary of our Healthcare Division, GlobalOne Healthcare Holding (GHH), has signed an exclusive licensing agreement with Cooper Pharma S.A. (Cooper) for Adalimumab. This agreement provides Cooper with exclusive rights to register, hold the marketing authorisation, and commercialise Adalimumab in Morocco.   Bioventure, which specialises in biosimilars and speciality generics, in/out-licensing, tech transfer, and

GlobalOne Healthcare, Yas Holding’s healthcare investment arm, acquires Pharma Distributor Al Ittihad Drug Store   GlobalOne Healthcare Holding (GHH), a Yas Holding division, announced the acquisition of a major UAE pharmaceutical distributor, Al Ittihad Drug Store (IDS), which will significantly expand GHH’s distribution coverage in the UAE.   The acquisition was completed in December, making

Yas Holding LLC (YHL) has completed the acquisition of Gulf Inject LLC (GI) from Ras Al Khaimah-based Gulf Pharmaceutical Industries (Julphar), a listed UAE-based pharmaceutical company. The 100% acquisition, which includes Gulf Inject’s Jebel Ali Free Zone branch, was completed through Yas Holding’s dedicated healthcare investment vehicle, GlobalOne Healthcare Holding LLC (GHH).   GHH’s healthcare

We are pleased to announce that last week Yas Holding LLC completed the acquisition of a significant majority shareholding in Geltec Healthcare FZE. Located in Dubai’s Jebel Ali area, Geltec Healthcare FZE is part of a renowned pharma and nutraceutical group with a global presence. The acquisition was completed through our dedicated healthcare investment group,

Yas Holding, has acquired a 2.5% stake in Alvotech and signed an agreement for an exclusive partnership and supply of some of their specialized products, which we will commercialize in the MENA region. The total partnership value, including the purchase of new shares, an upfront license payment, along with subsequent milestone payments is estimated to